
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio Inc has made significant strides in its RNA editing technology, particularly with the introduction of KRRO-121, a liver-targeted drug aimed at improving ammonia clearance in patients with conditions such as UCD and HE, which could lead to significant market opportunities worth approximately $3.5 billion combined. The recent preclinical data demonstrates KRRO-121’s ability to stabilize glutamine synthetase while maintaining glutamine levels, indicating a promising therapeutic approach with a strong pharmacoeconomic upside by potentially reducing hospitalizations and crises. With an IND filing anticipated in the second half of 2026 and a clear regulatory pathway ahead, Korro Bio's innovative approach positions it favorably in the evolving landscape of genetic medicines.
Bears say
Korro Bio Inc has faced significant challenges, including a recent selloff following negative results from its KRRO-110 AATD program and the nomination of KRRO-121 as its second RNA editing asset, which has raised concerns about its pipeline's viability. Key risks identified include potential delays in advancing pipeline candidates through clinical trials, failures to generate favorable clinical data, and long-term dilution risk, all of which could negatively impact investor sentiment and stock performance. Additionally, uncertainties regarding regulatory approvals and the risk of competition from new treatment methods could further diminish the attractiveness of Korro Bio's therapies, leading to considerable financial vulnerability.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares